International journal of cardiology · 2009
Long-term clinical outcome with titanium-nitride-oxide-coated stents and paclitaxel-eluting stents for coronary revascularization in an unselected population.
Сравнительное исследованиеСтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Karjalainen Pasi P, Annala Antti-Pekka, Ylitalo Antti, Vahlberg Tero, Airaksinen K E Juhani
Аннотация
BACKGROUND: The aim of this study was to evaluate long-term clinical events in patients treated with titanium-nitride-oxide-coated bio-active stents (BAS) and paclitaxel-eluting stents (PES) in routine clinical practice.
METHODS: All patients undergoing percutaneous coronary intervention (PCI) were eligible for this single-centre registry between May 2003 and November 2004. The primary end point of the study was major adverse cardiac events (MACE) at 3 years including myocardial infarction (MI), cardiac death and target vessel revascularization (TVR).
RESULTS: A total of 201 patients received BAS and 204 patients PES. In addition, during the same study period, 184 patients were treated with bare-metal stents (BMS) and 125 patients underwent CABG. Complete follow-up datasets were available in all patients. After 3 years of follow-up, the rate of MACE was 13.9% for BAS and 23.5% for PES (adjusted HR 2.0, 95% CI 1.2-3.2, p=0.006). This difference was mainly driven by a higher incidence of MI in the PES group (19.1%) compared with the BAS (7.5%) group (adjusted HR 3.2, 95% CI 1.7-5.8, p<0.001). The rate of MACE was 31.5% in the BMS group and 4% in the CABG group. At 3 years, stent thrombosis occurred in 15 patients in the PES (7.4%) group. There was no stent thrombosis in the BAS group.
CONCLUSIONS: After the 3 year follow-up, BAS resulted in better long-term outcome compared with PES with infrequent need for TVR.
METHODS: All patients undergoing percutaneous coronary intervention (PCI) were eligible for this single-centre registry between May 2003 and November 2004. The primary end point of the study was major adverse cardiac events (MACE) at 3 years including myocardial infarction (MI), cardiac death and target vessel revascularization (TVR).
RESULTS: A total of 201 patients received BAS and 204 patients PES. In addition, during the same study period, 184 patients were treated with bare-metal stents (BMS) and 125 patients underwent CABG. Complete follow-up datasets were available in all patients. After 3 years of follow-up, the rate of MACE was 13.9% for BAS and 23.5% for PES (adjusted HR 2.0, 95% CI 1.2-3.2, p=0.006). This difference was mainly driven by a higher incidence of MI in the PES group (19.1%) compared with the BAS (7.5%) group (adjusted HR 3.2, 95% CI 1.7-5.8, p<0.001). The rate of MACE was 31.5% in the BMS group and 4% in the CABG group. At 3 years, stent thrombosis occurred in 15 patients in the PES (7.4%) group. There was no stent thrombosis in the BAS group.
CONCLUSIONS: After the 3 year follow-up, BAS resulted in better long-term outcome compared with PES with infrequent need for TVR.